A Phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma

L. G. Feun, N. Savaraj, S. Hung, R. Reddy, L. Jeffers, P. Benedetto, A. S. Livingstone, B. Ardalan, J. U. Levi, T. Parker, E. R. Schiff

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

A Phase II trial of combination therapy with recombinant leukocyte interferon (αIFN) and doxorubicin was performed in patients with unresectable hepatocellular carcinoma. αIFN was administered at a starting dose of 20 x 106 U/m2 intramuscularly or subcutaneously with doxorubicin 20 mg/m2 intravenously weekly x 3 weeks followed by a 2-week period rest. There were 22 patients entered into the study. Among the 21 patients, there were 2 partial responses (10%), one minor response, and one patient had stable disease. Toxicity was generally tolerable, with fever, fatigue, and myelosuppression being the most common side effects. This combination of weekly recombinant leukocytic interferon and doxorubicin has modest and limited activity in hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)393-395
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number5
DOIs
StatePublished - 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this